KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Medial retropharyngeal nodal region sparing radiotherapy in nasopharyngeal carcinoma: five year analysis of open label, non-inferiority, multicentre, randomised phase 3 trial.

Shun-Xin Wang, Ya-Lan Tao, Tian-Sheng Gao, Ning Zhang, Guan-Qun Zhou, Fang-Yun Xie, Yuan Zhang, Rui Guo, Yi Yang, Yong-Jie Li, Shao-Qiang Liang, Yue-Can Zeng, Li Lin, Wen-Fei Li, Xu Liu, Cheng Xu, Yu-Pei Chen, Jia-Wei Lv, Li-Zhi Liu, Hao-Jiang Li, Ji-Bin Li, Hong-Mei Wen, Ying Sun, Ling-Long Tang, Xiao-Yu Liang, Jun Ma, Yan-Ping Mao

BMJ 392 e086050

PMID41916649
PMCIDPMC13036590
DOI10.1136/bmj-2025-086050
发表日期2026-03-31
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

OBJECTIVE: To determine the pre-specified long term efficacy (survival and swallowing function) and safety of medial retropharyngeal lymph node (MRLN) region sparing radiotherapy for non-metastatic nasopharyngeal carcinoma. DESIGN: Pre-specified five year analysis of an open label, non-inferiority, multicentre, randomised phase 3 trial. SETTING: Three Chinese medical centres between 20 November 2017 and 3 December 2018. PARTICIPANTS: Adults (18-65 years) with untreated, non-keratinising, non-metastatic nasopharyngeal carcinoma without MRLN involvement. INTERVENTIONS: Eligible patients were randomised (1:1; block size of four) to MRLN sparing radiotherapy or standard radiotherapy. Randomisation was stratified by institution and treatment modality (radiotherapy alone, concurrent chemoradiotherapy, or induction chemotherapy plus radiotherapy or concurrent chemoradiotherapy). MAIN OUTCOME MEASURES: The primary outcome was local relapse-free survival. The three year local relapse-free survival to assess the non-inferiority, with a margin of 8%, of MRLN sparing radiotherapy compared with standard radiotherapy has been reported previously. This updated report focuses on five year survival, toxicity, and quality of life. Additionally, a videofluoroscopic swallowing study and magnetic resonance imaging (MRI) measurements of pharyngeal contractors were used as objective measures of dysphagia RESULTS: This trial enrolled 285 patients in the MRLN sparing group and 283 patients in the standard group. At a median follow-up of 70 months, the MRLN sparing and standard groups had similar five year local relapse-free survival (89.2% (95% confidence interval (CI) 85% to 92%) versus 90.6% (87% to 94%); stratified hazard ratio 1.03 (95% CI 0.61 to 1.74); P=0.90) and overall survival (89.2% (85% to 93%) versus 90.3% (87% to 94%); stratified hazard ratio 1.06 (0.68 to 1.68); P=0.79). Updated safety profiles of the MRLN sparing group showed a lower rate of grade ≥1 dysphagia (45/206 (22%) v 70/216 (32%); P=0.01) and grade ≥2 dry mouth (33/206 (16%) v 55/216 (25%); P=0.02) and enhanced swallowing related quality of life (mean difference -11.9; P<0.001). Videofluoroscopy showed a lower prevalence of vallecular residue (49/66 (74%) v 62/62 (100%); P<0.001), pyriform sinus residue (32/66 (48%) v 45/62 (73%); P=0.01), coating of pharyngeal wall (7/66 (11%) v 17/62 (27%); P=0.01), pharyngeal transit time >1.0 s (1/66 (2%) v 7/62 (11%); P=0.03), and aspiration (8/66 (12%) v 18/62 (29%); P=0.03) in the MRLN sparing group. Additionally, MRI detectable late atrophy in the superior pharyngeal constrictor (mean thickness: 1.80 v 1.65 mm; P=0.005) and middle pharyngeal constrictor (2.34 v 2.15 mm; P=0.01) was less severe after MRLN sparing radiotherapy. CONCLUSIONS: MRLN sparing radiotherapy maintained uncompromised efficacy and better long term swallowing function by reducing radiation damage to pharyngeal contractors, supporting its use as a standard of care for non-metastatic nasopharyngeal carcinoma. TRIAL REGISTRATION: ClinicalTrials.gov NCT03346109.

KM 提取结果

1 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure4 个面板

Fig 2

Kaplan-Meier curves showing local relapse-free survival, overall survival, distant metastasis-free survival, and regional relapse-free survival in intention-to-treat population. CI=confidence interval; HR=hazard ratio; MRLN=medial retropharyngeal lymph node; RT=radiotherapy

Local_relapse-free_survival

Local relapse-free survival

Fig 2 · Panel Local_relapse-free_survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Local_relapse-free_survival 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Overall_survival

Overall survival

Fig 2 · Panel Overall_survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Overall_survival 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Distant_metastasis-free_survival

Distant metastasis-free survival

Fig 2 · Panel Distant_metastasis-free_survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Distant_metastasis-free_survival 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
Regional_relapse-free_survival

Regional relapse-free survival

Fig 2 · Panel Regional_relapse-free_survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Regional_relapse-free_survival 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig 1Trial profile. *14 patients >65 years, four <18 years, one with involved medial retropharyngeal lymph nodes, four with severe coexisting illness, and one with previous malignancy. †This included 206 disease-free survivors, as one patient who did not receive allocated radiotherapy was excluded from a total of 207. ‡This included 212 disease-free survivors and four patients who remained alive with disease progression after five years. MRLN=medial retropharyngeal lymph node
非 KM Figure